Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

prasco laboratories - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u), salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - fluticasone propionate/salmeterol diskus is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. fluticasone propionate/salmeterol diskus should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use fluticasone propionate/salmeterol diskus is not indicated for the relief of acute bronchospasm. fluticasone propionate/salmeterol diskus inhalation powder 250/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. fluticasone propionate/salmeterol diskus inhalation powder 250/50 mcg is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. fluticasone propionate/salmeterol diskus inhalation po

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/100 microgram(s) - salmeterol and fluticasone

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/250 microgram(s) - salmeterol and fluticasone

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/500 microgram(s) - salmeterol and fluticasone

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. seroflo ciphaler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u), salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - fluticasone propionate and salmeterol inhalation powder is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. fluticasone propionate and salmeterol inhalation powder should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use fluticasone propionate and salmeterol inhalation powder is not indicated for the relief of acute bronchospasm. fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. flut

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate and salmeterol inhalation powder is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. fluticasone propionate and salmeterol inhalation powder should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use fluticasone propionate and salmeterol inhalation powder is not indicated for the relief of acute bronchospasm. fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. flutica

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 20mg equivalent to 125 µg/dose;  ; salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol;   - aerosol inhaler, metered dose - 125µg/25µg - active: fluticasone propionate 20mg equivalent to 125 µg/dose   salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol   excipient: norflurane - seretide is indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of long-acting ?-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. patients who are symptomatic on "as needed" short-acting betaagonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 40mg equivalent to 250 µg/dose;  ; salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol;   - aerosol inhaler, metered dose - 250µg/25µg - active: fluticasone propionate 40mg equivalent to 250 µg/dose   salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol   excipient: norflurane - seretide is indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of long-acting ?-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. patients who are symptomatic on "as needed" short-acting betaagonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 8mg equivalent to 50 µg/dose;  ; salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol;   - aerosol inhaler, metered dose - 50µg/25µg - active: fluticasone propionate 8mg equivalent to 50 µg/dose   salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol   excipient: norflurane - seretide is indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of long-acting ?-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. patients who are symptomatic on "as needed" short-acting betaagonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.